Jones Trading analyst Soumit Roy reiterated a Buy rating and $30.00 price target on Precision BioSciences Inc. (NASDAQ: DTIL)

The analyst commented, "Precision held a virtual KOL call and announced the Ph1/2 trial design for PBGENE-DMD in Duchenne Muscular Dystrophy (DMD) Exons 45-55 (watch replay here). Site activation is ongoing and initial data from 3-5 patients are expected by YE'26. Safety is a focus for the readout given AAV delivery, and Precision is using a triple immune modulation regimen (eculizumab, steroids, and sirolimus). The key efficacy biomarker is % dystrophin at 12 weeks. Management guided to a minimum of 5% muscle content-unadjusted dystrophin as the bar for clinical benefit, but we note that dystrophin is expected to increase over time because satellite cells also undergo editing. We view PBGENE-DMD as therapeutically analogous to exon skipping but with the advantage of one-time dosing and broader addressable population (up to 60% of DMD patients). Aside from DMD, Precision will have additional cHBV data throughout 2026. As of 4Q25, DTIL has $137.2M in cash, with runway through 2028.Reiterate Buy and $30 PT."

For an analyst ratings summary and ratings history on Precision BioSciences Inc. click here. For more ratings news on Precision BioSciences Inc. click here.

Shares of Precision BioSciences Inc. closed at $6.93 yesterday.